Documentation
Description:
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Coverage
Spatial:
United Kingdom, England
Provenance
Temporal
Accrual Periodicity:
Other
Start Date:
01 January 2015
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Other
Data Controller:
The Institute of Cancer Research
Data Processor:
Not Applicable
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en
Formats:
In Progress